Aurintricarboxylic acid
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561329

CAS#: 4431-00-9

Description: Aurintricarboxylic acid (ATA) is a strong inhibitor of topoisomerases and other nucleases. It readily polymerizes in aqueous solution, forming a stable free radical that inhibits protein-nucleic acid interactions. It is a potent inhibitor of ribonuclease and topoisomerase II by preventing the binding of the nucleic acid to the enzyme.

Chemical Structure

img
Aurintricarboxylic acid
CAS# 4431-00-9
Instruction

Theoretical Analysis

MedKoo Cat#: 561329
Name: Aurintricarboxylic acid
CAS#: 4431-00-9
Chemical Formula: C22H14O9
Exact Mass: 422.06
Molecular Weight: 422.350
Elemental Analysis: C, 62.57; H, 3.34; O, 34.09

Price and Availability

Size Price Availability Quantity
5g USD 200
25g USD 420
Bulk inquiry

Synonym: Aurintricarboxylic acid; ATA; NSC-4056; NSC 4056; NSC4056;

IUPAC/Chemical Name: 5-[(3-Carboxy-4-hydroxyphenyl)-(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]-2-hydroxybenzoic acid

InChi Key: GIXWDMTZECRIJT-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H14O9/c23-16-4-1-10(7-13(16)20(26)27)19(11-2-5-17(24)14(8-11)21(28)29)12-3-6-18(25)15(9-12)22(30)31/h1-9,23-24H,(H,26,27)(H,28,29)(H,30,31)

SMILES Code: O=C(O)C1=CC(/C(C2=CC=C(O)C(C(O)=O)=C2)=C3C=C(C(O)=O)C(C=C/3)=O)=CC=C1O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 422.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yoo J, Kim JH, Robertson KD, Medina-Franco JL. Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNMT1 inhibitor. Adv Protein Chem Struct Biol. 2012;87:219-47. doi: 10.1016/B978-0-12-398312-1.00008-1. Review. PubMed PMID: 22607757; PubMed Central PMCID: PMC3837394.

2: Zhan P, Li Z, Liu X. Cosalane and its analogues: a unique class of anti-HIV agents. Mini Rev Med Chem. 2010 Sep;10(10):966-76. Review. PubMed PMID: 20540707.

3: De Clercq E. The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. Med Res Rev. 2011 Jan;31(1):118-60. doi: 10.1002/med.20179. Review. PubMed PMID: 19844936.

4: Clemetson KJ, Clemetson JM. Platelet GPIb complex as a target for anti-thrombotic drug development. Thromb Haemost. 2008 Mar;99(3):473-9. doi: 10.1160/TH07-12-0718. Review. PubMed PMID: 18327394.

5: De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther. 2006 Apr;4(2):291-302. Review. PubMed PMID: 16597209.

6: Matsuno H. [Pharmacological analysis of integrin function: inhibition of vascular stenosis and identification of a novel antiplatelet substance]. Nihon Yakurigaku Zasshi. 2000 Mar;115(3):143-50. Review. Japanese. PubMed PMID: 10876799.

7: Hoylaerts MF. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor. Verh K Acad Geneeskd Belg. 1997;59(3):161-83. Review. PubMed PMID: 9490916.

8: Cidlowski JA, King KL, Evans-Storms RB, Montague JW, Bortner CD, Hughes FM Jr. The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system. Recent Prog Horm Res. 1996;51:457-90; discussion 490-1. Review. PubMed PMID: 8701091.

9: De Clercq E, Snoeck R. [Current acquisitions in antiviral drugs (anti-HIV)]. J Pharm Belg. 1992 Jul-Aug;47(4):317-22. Review. French. PubMed PMID: 1383488.

10: Phelps KR, Vigorita VJ, Bansal M, Einhorn TA. Histochemical demonstration of iron but not aluminum in a case of dialysis-associated osteomalacia. Am J Med. 1988 Apr;84(4):775-80. Review. PubMed PMID: 3041812.

11: De Clercq E. Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS). J Med Chem. 1986 Sep;29(9):1561-9. Review. PubMed PMID: 2427720.

12: Clark RA, Krueger GL. Aluminon: its limited application as a reagent for the detection of aluminum species. J Histochem Cytochem. 1985 Jul;33(7):729-32. Review. PubMed PMID: 3891845.